Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.

Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.